Sean Nicholson is a professor in the Department of Policy Analysis and Management (PAM) at Cornell University, the director of the Sloan Program in Health Administration, and a research associate at the National Bureau of Economic Research. Prior to joining the PAM department in 2004, Professor Nicholson was a faculty member in the Health Care Systems Department at The Wharton School of the University of Pennsylvania. He worked for four years as a management consultant with APM and taught high school for two years before enrolling in graduate school. Professor Nicholson received a B.A. from Dartmouth College in 1986 and a Ph.D. in economics from the University of Wisconsin-Madison in 1997.
Biotech and Pharmaceutical
Management SummitSeptember 29 and 30, 2023 at Cornell Tech in NYC
- View slide #1
- View slide #2
- View slide #3
Cornell University invites professionals from the biotech and pharmaceutical industries to join industry experts, policy makers, and thought leaders for an immersive experience at the Cornell Tech campus in New York City. Over the course of two days, you will have the opportunity to hear from Cornell faculty conducting leading-edge research in areas ranging from technology’s expanding role in improving health equity to exploring the health insurer perspective on pharmaceuticals. Small panel discussions will provide an opportunity to address today’s most urgent industry topics.
- 5:00pm – 7:00pm Check-in at Graduate Hotel
- 6:30pm Welcome Reception – Anything At All at The Graduate Hotel
- 8:00am Breakfast at the Verizon Executive Education Center
- 9:00am – 10:15am Welcome: Sean Nicholson and Keynote address: Angela Hwang
- 10:15am – 10:30am Break
- 10:30am – 12:00pm Concurrent Sessions
- The State of the Biotech Industry – Arnaub Chatterjee and Saif Rathore
- Business Development: Private Equity, Alliances, and M&A – Stephanie Wisner and Andrew Weisenfeld
- 12:00pm – 1:00pm Lunch
- 1:00pm – 2:15pm Concurrent Sessions
- Diversity, Equity, and Inclusion in Clinical Trials the Biopharmaceutical Industry – Paul Evans, Shawn Malloy, and Deborah Arrindell
- Biopharmaceutical Innovation: Charting the New and Stabilizing the Old – Don Drakeman and Carter Dredge
- 2:15pm – 2:30pm Break
- 2:30pm – 4:00pm Keynote address: Bob Langer
- 4:00pm – 4:30pm Daily recap
- 6:00pm – 9:00pm Cocktails and networking – the Panorama Room at The Graduate Hotel
- 8:00am Breakfast at the Verizon Executive Education Center
- 9:00am – 10:15am Value and Access: Payer perspective in the U.S. & Internationally – Sandeep Duttagupta, Amy Mulderry, and Julie Eagle
- 10:15am – 10:30am Break
- 10:30am – 12:00pm Digital Therapeutics – Jeff Abraham and David Artz
- 12:00pm – 1:00pm Lunch
- 1:00pm – 2:15pm Concurrent Sessions
- Biopharmaceutical Companies’ Role in Personalized Health Care – Tanzeem Choudhury and Kelly Haenlein
- Biopharmaceutical Policy Perspective – Jeremy Allen and Sean Nicholson
- 2:15pm – 2:30pm Break
- 2:30pm – 4:00pm Emerging Disruptive Trends in Biopharma: Barriers to and Incentives for Adoption – Joydeep Ganguly and Jaqueline Vaderpuye-Orgle
- 4:00pm – 4:30pm Daily recap and Conclusion
Key Course Takeaways
- Understand the research and development process for a drug, including how a company makes key drug development decisions
- Articulate the scientific steps needed to get a drug approved by the FDA
- Describe the key patents on a drug, when they were filed, and how the timing affects market exclusivity
- Conduct competitive research in a given drug class or disease area
- Anticipate the pros and cons of a merger, acquisition, or alliance opportunity based on empirical research
- Articulate and critique the market strategy for a given drug class or disease area
- Describe how the science, R&D, and patent decisions affect the drug's performance over its life cycle in an uncertain environment
- Evaluate the lifecycle management strategy for a branded firm to maximize its market exclusivity and a strategy for a generic or biosimilar firm to enter the market expeditiously
- Describe how biotech and pharma firms set prices and negotiate with health insurers
- Describe how firms decide whether to develop a drug independently or codevelop with another firm and how that decision affects the financial outlook of a company
- Articulate how the optimal marketing strategy for a drug differs based on the three key decisions made early in its development cycle and on the drug's performance in clinical trials
How It Works
- View slide #1
- View slide #2
- View slide #3
- View slide #4
- View slide #5
- View slide #6
Tanzeem Choudhury is a professor in Computing and Information Sciences at Cornell Tech, where she holds the Roger and Joelle Burnell Chair in Integrated Health and Technology. At Cornell, she directs the People-Aware Computing Group and leads the Precision Behavioral Health Initiative, focused on advancing the future of technology-assisted well-being. Professor Choudhury cofounded HealthRhythms Inc, a company whose mission is to add a layer of behavioral health into all of healthcare. She is also the Senior Vice President of Digital Health at Optum Labs. Prior to Cornell, Professor Choudhury was an Assistant Professor in Computer Science at Dartmouth College. She received her Ph.D. from the MIT Media Laboratory.
Professor Choudhury has received the NSF CAREER award (2008), TR35 award (2008), TED fellowship (2009), PopTech Science fellowship (2010), Kavli fellowship (2011), Ubicomp 10-Year Impact Award (2016, 2022). She has been elected as an ACM Fellow (2021) and inducted into the ACM SIGCHI Academy (2022).
Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. In 1970, Dr. Langer received his B.S. with distinction in Chemical Engineering and was awarded his Sc.D. from MIT in 1974. He has written over 1,500 articles, which have been cited over 383,000 times; his h-index of 307 is the highest of any engineer in history and the second highest of any individual in any field. Dr. Langer’s patents have been licensed or sublicensed to over 400 companies; he is a cofounder of a number of companies, including Moderna. Dr. Langer served as chairman of the FDA’s Science Board (its highest advisory board) from 1999 to 2002.
Dr. Langer is the recipient of over 220 awards, including both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of three living individuals to have received both these honors), Cornell Entrepreneur of the Year, the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (the highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, Dreyfus Prize in Chemical Sciences, BBVA Frontiers of Knowledge Award in Biomedicine, and the Balzan Prize. Dr. Langer holds 40 honorary doctorates, including Harvard, Yale, Columbia, and Northwestern, and he has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences, and the National Academy of Inventors.
Joydeep Ganguly is Senior Vice President of Corporate Operations at Gilead Sciences. In his current role, Mr. Ganguly is accountable for several strategic functions, including corporate engineering, capital and infrastructure strategy, corporate real estate, risk management, operations research, and global procurement. Serving as the Chief Sustainability Officer for the organization, he also leads Gilead’s environmental sustainability strategies globally. He is a member of the company’s executive ESG committee as well as a board member of the Gilead Foundation. Prior to Gilead, Mr. Ganguly spent 10 years at Biogen in roles of increasing responsibility in the areas of technical operations, manufacturing, and supply chain. In his role as Vice President and General Manager of Biogen’s global manufacturing network, he oversaw the company’s multiscale biologics and small-molecule operations, and he led general operations for the company’s presence in North Carolina.
A past board member of the North Carolina Biosciences Organization (NCBIO) and the North Carolina Museum of Life and Sciences, Mr. Ganguly currently serves on the Board of Directors of Bay Area Council, Biocom, and Science from Scientists, and he is a trustee at Town School for Boys. He earned an M.S. in Electrical Engineering from the University of Notre Dame, an MBA from North Carolina State University, and an MHA from Cornell University. Mr. Ganguly was recently recognized by the National Diversity Council as a Top 50 Diverse Leader in California and was awarded the Leadership Excellence Award by the California Diversity Council.
Arnaub Chatterjee is Chief Product and Solutions Officer at TriNetX, a health technology platform focused on improving clinical research, study design, safety, and clinical trial recruitment. He also serves as Senior Advisor at the Carlyle Group in evaluating investments in the life sciences and healthcare sectors. Additionally, Mr. Chatterjee is passionate about teaching and is a member of the faculties in the Department of Health Care Policy at Harvard Medical School and in the Department of Policy Analysis and Management at Cornell University.
Prior to TriNetX, Mr. Chatterjee was Senior Vice President and head of Medidata AI, the data sciences business of Medidata Solutions. At Medidata, he was building novel software and data science solutions in clinical, commercial, and imaging analytics for the life sciences industry. Before his time at Medidata, Mr. Chatterjee was Associate Partner in the Pharmaceutical and Medical Products group at McKinsey & Company, where he supported clients on topics such as R&D strategy, portfolio prioritization, and go-to-market. He also held roles as Director of Data Science and Insights within Merck’s Center for Real-World Evidence and as a technology advisor in the Obama administration in the Department of Health and Human Services (HHS).
Mr. Chatterjee’s work has been published in multiple peer-reviewed journals such as the Harvard Business Review and Nature, and he has presented at conferences ranging from South by Southwest to the American College of Cardiology. He serves as an advisor and board member to a number of organizations, including the World Economic Forum’s Council for Biotechnology; BioSpring, a life sciences growth equity firm; and CityPods, a solution to scale temporary housing. Mr. Chatterjee holds graduate degrees in health administration (MHA) and public administration (MPA) from Cornell University, and he received his undergraduate degree from the University of Michigan.
Saif is a member of the Healthcare practice, with deep expertise in the use of advanced analytics across the health care ecosystem.
Saif has worked with biotechnology, large pharmaceutical companies, medical technology manufacturers, provider systems, payors, academic organizations, government entities, not for profits, and investment groups in North America, Europe, and Asia.
Saif provides expertise in a broad range of topics in health care, including:
- Advanced analytics: Use of AI and machine learning in research and development and medical affairs in pharma, biotech, and med tech; provider AI use cases, including deployment and evaluation
- Strategy: Portfolio review, platform build, product launch, indication expansion, value and access
- Real world data: Development of RWD capabilities, programs, delivery of RWE insights
- Diligence: Evaluation of pre-clinical and clinical assets, research platforms, medical technology, digital health offerings for investment (seed to IPO) and acquisition
- Cardiometabolic disease: 130+ peer reviewed articles in cardiovascular disease, diabetes, and health services research, including professional position statements, national guidelines
Previous Work Experience:
- SVP Strategy at Cellarity, a $600M AI-enabled biotech in the Flagship Pioneering ecosystem
- Joint position as Global Head of Data and Analytics Innovation at Cigna and Express Scripts and Medical Director of Cigna Ventures
- Associate Principal and Medical Director, McKinsey & Company
- Lecturer, Yale University School of Medicine
- Internal medicine residency at Massachusetts General Hospital
- MD from Yale University School of Medicine
- PhD (epidemiology) from Yale University
- MPH (public health) from University of North Carolina at Chapel Hill School of Public Health
- AB (history, psychology, cognitive studies) from Cornell University
Sandeep Duttagupta, Ph.D., is currently the Vice President of Global Pricing and Market Access at Alnylam. Dr. Duttagupta’s responsibilities include overseeing Alnylam’s pricing and access strategies for its entire portfolio, managing the global governance around access, and working closely with regional teams to maximize the value of their programs, and playing a key role in developing future innovative access programs per Alnylam’s Patient Access philosophy.
Dr. Duttagupta has over 25 years of global industry and management consulting experience, specializing in global pricing and market access for biopharmaceutical products. Most recently he was a partner at DRG/Clarivate Consulting and Practice Lead for Global Pricing and Market Access. Dr. Duttagupta joined erstwhile DRG Consulting in 2018 and advised biopharmaceutical clients in their go-to-market pricing and patient access strategies across the U.S., Europe, Japan, China, and emerging markets. He worked with both government and private healthcare payers across the globe to help key pharma and biotech clients maximize access to patients for innovative medicines.
Prior to DRG/Clarivate, Dr. Duttagupta was at CBPartners, a NYC-based boutique life sciences strategy consulting firm specializing in value, access, and pricing, where he held the role of Senior Vice President of Business Development. During his tenure, he helped expand the firm’s business into a substantial number of new clients across various geographies. Prior to this, Dr. Duttagupta spent 17 years at Pfizer, across positions of increasing responsibility, first within Global and U.S. HEOR, then for 10 years in various Global Pricing and Market Access functions. His last position was as the Vice President of P&MA for Pfizer’s Emerging Market Business Unit, where he had the opportunity to reshape internal thinking and business models in low- to middle-income countries across Pfizer’s portfolio. Additionally, on behalf of PhRMA, Dr. Duttagupta was often the face of the pharmaceutical industry in shaping industry-friendly government policies in a large number of countries.
Dr. Duttagupta also serves as an Executive Board member for privately held Aquavit Pharmaceuticals and Celanese (NYSE: CE).
Stephanie A. Wisner co-founded the biotech start-up, Centivax, where she is now Chief Business Officer. She has also advised multiple biotech start-ups on business and commercialization strategy through her consulting business, BioVenture Advising LLC, and spent several years at ARCH Venture Partners. In 2022, she was named to the Forbes 30 Under 30 list for Healthcare. She completed her MBA at the University of Chicago Booth School of Business, with concentrations in finance, accounting, and entrepreneurship. She received her Bachelor’s Degree in chemistry and chemical biology from Cornell University and was awarded the Einhorn Discovery Research Grant for her independent research on cancer. Her book, Building Backwards to Biotech, was an Amazon #1 New Release in the category of Biotechnology. The book is currently taught as part of bioentrepreneurial programming at multiple top institutions, including Dartmouth College, Cornell University, and others. She is also an Entrepreneur-in-Residence at Cornell University. While she no longer gets as much time in the lab, she enjoys the travel and continuous learning this career involves. You can reach Stephanie at bioventureadvising.com.
Andrew Weisenfeld has been an investment banker since 1989. He became a partner at MTS Health Partners in January 2008 and is now one of the firm’s managing partners, primarily responsible for the development of the life sciences M&A advisory practice. Prior to joining MTS, Mr. Weisenfeld was a Managing Director in Banc of America Securities’ Corporate and Investment Banking Healthcare Group. He co-led the firm’s life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Bank of America in 2003, Mr. Weisenfeld was a managing director at J.P. Morgan and its predecessor company, Chase Securities, leading its Healthcare M&A business across all sectors of healthcare from the middle of 1997 to the beginning of 2003. Prior to joining Chase, he spent over five years in the M&A Group at Merrill Lynch.
Throughout his career, Mr. Weisenfeld has worked on a wide range of advisory transactions including acquisitions, sale transactions, and strategic relationships. Selected life sciences transactions include the sale of Seagen to Pfizer for over $44 billion, the sale of Veloxis to Asahi, the acquisition of Alder by Lundbeck, the merger of Keryx with Akebia, the sale of Colucid to Lilly, the sale of Celator to Jazz Pharmaceuticals, Otsuka’s acquisitions of Avanir and Neurovance, and a number of the most prominent reverse mergers. Mr. Weisenfeld is a board member of Public Health Solutions, a New York-based nonprofit. He is also an active alumnus of Cornell University, acting as a member of the scientific advisory committee of Weill Cornell Medical School’s Daedalus Fund for Innovation as well as a member of both the Cornell Brooks School of Public Policy Advisory Council and Cornell Dyson School’s Undergraduate Program Advisory Council. Mr. Weisenfeld holds an MBA from The Wharton School at the University of Pennsylvania and a B.S. from Cornell University.
Don Drakeman was the founding CEO of the biotech company that created the cancer immunotherapy treatments recognized in the 2018 Nobel Prize for Medicine. He is currently a Venture Partner at Advent Life Sciences, a Fellow and Co-Lead of the Biopharmaceutical Initiative at the University of Cambridge Judge Business School, and Distinguished Research Professor in the Center for Citizenship and Constitutional Government at the University of Notre Dame. He is a co-author of From Breakthrough to Blockbuster: The Business of Biotechnology, published in 2022 by Oxford University Press, which has been named a Financial Times “Top Business Title.” His publications have been cited in numerous patents and by the Supreme Court of the United States. A graduate of Dartmouth College and Columbia Law School, he received a Ph.D. from Princeton University. He has been a founder, adviser or board member of biotechnology firms in nine different countries in North America and Europe.
Mr. Dredge is the Senior Vice President & Lead Futurist at SSM Health and oversees research and development, innovation, and new venture activities, and serves on numerous boards, including four pharmaceutical companies: Navitus Health Solutions (a PBM), Lumicera Health Services (a specialty pharmacy), and Civica Rx and CivicaScript (two generic manufacturers). Prior to becoming Lead Futurist, Mr. Dredge served as Chief Transformation Officer and Chief Strategy Officer for SSM Health. Prior to SSM Health, Mr. Dredge served as an executive at Intermountain Health. He is a Lecturer in the Jeb E. Brooks School of Public Policy at Cornell University, teaching a graduate course on alternative healthcare payment design, and is the first American to be accepted into a specialized Business Doctorate program at the University of Cambridge in the UK designed for senior executives with the potential to reshape management theory within their domain. Mr. Dredge is a Fellow of the fifth class of the Aspen Institute Health Innovators Fellowship and a member of the Aspen Global Leadership Network. With his rare combination of industry, academic, and entrepreneurial experience, he has been recognized by Modern Healthcare magazine as one of the ‘Top 25 Innovators’ in the United States.
Amy Mulderry is Senior Vice President and Chief Development Officer at Elevance Health, Inc. In this role, she leads the company’s inorganic growth strategy, including joint ventures and minority investments, mergers and acquisitions, and corporate integration. In 2022, the role of CFO for Carelon was added to her responsibilities. Prior to joining Elevance Health, Ms. Mulderry spent 20 years as a healthcare industry investor managing equity portfolios at top-tier asset management firms.
Ms. Mulderry served as managing partner and portfolio manager for Tavio Capital LLC, where she managed a $600 million long/short equity healthcare hedge fund as a subadvisor to the Blackstone Equity Managed Account Platform and a healthcare-dedicated beta-neutral fund with a primary focus on healthcare services and medical device sectors. Ms. Mulderry also served in previous healthcare portfolio management roles with Citadel Global Equities, SAC Capital, Salomon Brothers Asset Management, and CIBC World Markets Corp. She earned her Bachelor of Arts from Cornell University,
Jackie is a Vice President and the Global Head of the Advanced Analytics Unit with experience in conducting empirical research to underscore the differentiated value of assets across a range of therapeutic areas. In her role at Parexel, Jackie is responsible for providing technical expertise and oversight on data visualization, meta-analysis, AI, and general statistical analysis workstreams.
Jackie is a health economist with over 20 years of progressive experience in the application of econometric principles and statistical analysis to both clinical and real-world data. Prior to joining Parexel, she worked as a Senior Manager in Global Health Economics at Amgen. Jackie also worked as a Director of Research Operations and Senior Economist at Precision Health Economics where she was responsible for developing proposals and executing projects on several oncology and immune-oncology assets to support regulatory approval, value messaging, and market access in various regions. In addition, Jackie has held research and consulting roles at Endurance Reinsurance, Analysis Group, and the Public Economics and Macroeconomics Divisions of the World Bank in Washington DC. Jackie completed her PhD at Cornell University following a pre-doctoral in economics at Yale University.
Paul Evans, PhD has worked in the pharmaceutical industry for over 30 years. He is currently President and CEO of Velocity Clinical Research, which owns and operates investigator sites across multiple therapeutic areas in the US and Europe. From a private equity start-up in 2018 Velocity has grown to be the largest SMO (Site Management Organisation) in the world under Paul’s leadership and is focused on solving the delays caused by the inherent inefficiencies of the clinical research process. This was particularly critical during Operation Warp Speed to develop the COVID19 vaccines in which Velocity contributed more patients than any other organization.
He started his career establishing and managing research sites in the UK and was a founder of one of the first European SMOs. Paul joined the CRO sector in 2005 building global site networks that partnered strategically rather than being selected tactically by the CRO and continued to work on innovative patient recruitment campaigns in some of the most challenging environments across all continents. In two of the world’s largest CROs he has led global functions that have included site intelligence, study start-up, feasibility, site contracting, patient recruitment and Investigator payments. Few people have had the opportunity to spend so much of their careers working both on the investigator and sponsor sides of the GCP divide and this breadth of experience gives him a unique insight into the challenges faced by the drug development industry.
Shawn Malloy is VP of Marketing for Lindus Health the anti-CRO for life science pioneers delivering clinical trials faster, fairer, and friendlier. Lindus uses technology to reach patients in their communities from all backgrounds to give them access to cutting edge clinical trials. Shawn has a long career in the clinical trials space on both the pharma sponsor side and startup health tech innovators. Shawn has an MBA in Healthcare Marketing, and holds a Bachelor’s and Master’s degree in Engineering from Cornell University.
Angela Hwang is the Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer and a member of its Executive Leadership Team. She and her organization, comprised of over 26,000 colleagues, are responsible for delivering all 600 of Pfizer’s medicines and vaccines to patients in 185 countries. In 2022, more than 1.3 billion people received a Pfizer therapy that protected and improved their health. Under Angela’s leadership, Pfizer Biopharma generated $100 billion in 2022 revenues.
Pfizer’s Biopharma business addresses major global health priorities, including cancer, COVID-19, infectious diseases, inflammation & immunology, rare diseases, cardiovascular/metabolic disorders, and preventative care with vaccines. But Angela’s work goes beyond making medicines available. She is equally focused on creating and expanding collaborations with health insurers, governments, policymakers, and global health stakeholders around the world to come up with new and better ways to meet health challenges and make medicines accessible and affordable for all.
In 2020, Angela and Pfizer’s Biopharma team launched the world’s first COVID-19 vaccine and, one year later, the first oral antiviral treatment. Though vaccines often take many years to develop distribute, Angela and her team — inspired by a relentless focus on helping patients — made the impossible possible.
Angela’s commitment to health equity has deep roots. Her experience growing up as an Asian girl in South Africa during the apartheid era shaped her worldview. It helps explain why, after 27 years at Pfizer, she continues to find purpose and common cause with her Pfizer colleagues to bring more breakthroughs to patients, no matter who they are or where they live. Under Angela’s leadership, Pfizer launched An Accord for a Healthier World, a first-of-its-kind initiative to enable sustained, equitable access to all of Pfizer’s medicines and vaccines in 45 lower-income countries. The Accord has the potential to improve the health of 1.2 billion people and transform the healthcare ecosystem in those countries.
Beyond her work at Pfizer, Angela serves on the Board of Directors of UPS, the European Federation of Pharmaceutical Industries and Associations, the U.S. China Business Council, Cornell’s Johnson Graduate School of Management Advisory Council, and the Pfizer Foundation, which uses the power of philanthropy to improve global health.
Angela is consistently ranked among the world’s top leaders in healthcare and business by publications including Crain’s, Business Insider, Forbes, and Fortune, which placed her in the top 20 Most Powerful Women in Business three years in a row. Angela is also an honoree of A100, which recognizes the most impactful Asian American and Pacific Islander (AAPI) leaders. In 2021, she received the President’s Award from the National Diversity Council for championing diversity, equity, and inclusion. Cornell University named Angela a Robert S. Hatfield Economic Fellow in 2022. In 2023, she was recognized as a Ascend A-list Honoree for her professional achievements as an Asian American leader. Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and her MBA from Cornell. Angela and her husband are proud parents of a teenage daughter and son. Angela is a fierce advocate for women’s leadership and sustainable global health equity. You can follow Angela on LinkedIn and on Instagram using @angelahwangpfizer.
Julie Eskay Eagle is an advisor to early stage health care companies and an Executive-in-Residence for Cornell University, working with life sciences innovators across Cornell’s campuses. Ms. Eagle has spent the past decade working in startups in the pharmaceutical and digital health sectors. In 2019 she founded and led SaaS platform company DragonflyPHD to profitability, providing a vital information platform to independent pharmacies and urgent care operators during the pandemic. Prior to becoming an entrepreneur, Ms. Eagle was Head of Health Care Investments for The Wellcome Trust from 2000-2010, managing a $1 bn portfolio of health care investments focused on early-stage companies. Ms. Eagle began her career in consulting and investment banking with McKinsey and Lazard. She is a member of the Board of Advisors of the Sloan Health Care Administration program at the Jeb Brooks School of Public Policy at Cornell University and graduated with a BS degree in Biomedical Ethics from Cornell University and an MBA from Columbia Business School.
Jeff Abraham co-leads the Digital Health and Health IT Practice at Health Advances. His nearly 20-year career in healthcare spans digital health and therapeutics, MedTech, biopharma, and healthcare services. He holds extensive expertise related to digital health go-to market strategy commercialization, global market access, product development, and evidence generation.
Jeff currently serves as a Task Group Lead for the National Council of Prescription Drug Programs, a Task Group Lead for the Digital Therapeutics Alliance, representative on the Founding Members Council for the Digital Medicine Society, and other advisory roles for payer organizations and professional societies.
Prior to joining Health Advances, Jeff held executive roles in market access, trade, and commercial functions at Akili Interactive, an industry leading digital therapeutics company. During his time at Akil Interactive, Jeff focused on payer strategy, marketing, sales, reimbursement, pricing, strategic partnerships, evidence generation, distribution, launch planning and execution. Before Akili Interactive, Jeff was Senior Director for the Medicines Company in their Value Development department. He supported commercialization and global launch of novel drug device combo and the development of additional perioperative and cardiovascular products. Before The Medicines Company, Jeff was a consultant for GfK working in global market access and commercialization. His work spanned numerous therapeutic areas across drug, devices, and diagnostics. Jeff holds a Master of Science in Physical Therapy and an MBA with a specialization in Health Sector Management from Boston University.
Chiara Galli is Assistant Professor of Comparative Human Development at the University of Chicago. She received her Ph.D. in Sociology from the University of California, Los Angeles, in 2020 and was a postdoctoral fellow at Cornell from 2020 to 2022.
Dr. Galli is the author of the book “Precarious Protections: Unaccompanied Minors Seeking Asylum in the United States” (University of California Press. 2023), an ethnographic study that chronicles the experiences and perspectives of Central American unaccompanied minors and their immigration attorneys as they pursue applications for refugee status in the U.S. asylum process. For more information on Dr. Galli’s research, visit www.gallichiara.com.
Jeremy Allen joined Spark Therapeutics in March 2017 as its Head of Government Affairs. In this role, Jeremy oversees the development and execution of Spark’s government affairs and policy strategy at the federal, state, and international level. Prior to joining Spark, Jeremy spent six years at AHIP in various roles, culminating in him leading its Federal Affairs department. As AHIP’s senior lobbyist, Jeremy had responsibility for developing and executing AHIP’s federal advocacy efforts. During this time he was twice named one of The Hill newspaper’s “Top Lobbyists.” Previously, Jeremy lobbied for two pharmaceutical companies and spent nearly three years working on Capitol Hill for both the House Energy and Commerce Committee and Rep. Mike Bilirakis. Jeremy began his career as a Presidential Management Intern with the Centers for Disease Control and Prevention. Jeremy received his B.S. in industrial and labor relations and M.P.A. from Cornell University. He lives with his wife Ashley and two children in Washington, DC.
David Artz, MD, MBA is an Associate Professor (Courtesy) of Population Health in the Division of Health Informatics at Weill Cornell Medicine and co-founder of Zedimed, where he serves as a strategy consultant to health system and pharmaceutical clients. His primary areas of expertise are payment and policy with a focus on precision medicine. Dr. Artz is board certified in Internal Medicine and maintains a weekly clinic.
He was co-founder of Standard Molecular, a genomics informatics company. He was Chief Medical Information Officer at Memorial Sloan Kettering Cancer Center for 12 years and held this same role at Northwestern Memorial Hospital in Chicago.
Dr. Artz is a currently a Senior Fellow of Healthcare Administration at Rutgers’ Bloustein school of public policy. He received an MBA in finance and healthcare management from Northwestern University’s Kellogg School of Management and an MD from West Virginia University.
Dr. Arrindell graduated from Cornell University in 1979 with a BS in biology from CALS. Dr. Arrindell attended Yale University School of Medicine where she received her combined MD-MPH. Dr. Arrindell completed an internship in pediatrics at the University of Maryland Medical Center, and a residency/fellowship in anesthesiology and critical care at the Johns Hopkins Medical Center in Baltimore, Maryland. Following graduation from law school (University of Maryland School of Law), Dr. Arrindell entered the pharmaceutical industry where she has been for the last 20 years working in pharmacovigilance. Dr. Arrindell has worked at a number of large pharmaceutical companies including Roche, Wyeth (now Pfizer), Johnson and Johnson, and Amgen. At the end of October of 2020, Dr. Arrindell joined Global Blood Therapeutics, as Vice President of Pharmacovigilance and Risk Management. Global Blood Therapeutics, located in San Francisco, was a company whose mission was to provide on a global level, a functional cure for those suffering from sickle cell disease. GBT was acquired by Pfizer Inc, in October of 2022. Dr. Arrindell has been a long standing member of many Cornell organizations including: CBAA, PCCW, Cornell Club of Los Angeles, CAAAN (prior co-chair LA chapter), co-chair Mosaic Programming committee, Cornell Council member, and the Dean’s CALC’s Advisory Council. In 2022, Dr. Arrindell joined the Cornell University Board of Trustees, as an alumni elected trustee. In 2022, Dr. Arrindell endowed the Deborah Arrindell Endowment Scholarship for Health Equity in the department of Global Development at Cornell University. The gift was meant to honor the work done by staff at Global Blood Therapeutics , under the leadership of Dr. Ted Love (a classmate of Dr. Arrindell at Yale University School of Medicine), many of whom worked tirelessly to make a difference in the lives of patients with sickle cell anemia.
Kelly Haenlein leads Roche’s personalized healthcare ecosystem efforts at Roche. She and her teams collaborate and co-create with external partners to enable sustainable healthcare systems that make personalized healthcare accessible to patients worldwide. They also support the market assessment and commercial deployment of Roche digital and integrated healthcare solutions.
Prior to this global role, Kelly spent 3 years as Director of Strategic Partnerships & Initiatives in Oncology at Genentech. Her team’s scope spanned the development and execution of strategies driven by advances in real world evidence and technology in oncology practice, as well as collaborations with external stakeholders. Prior to joining Cross BioOncology in December 2015, Kelly was Director of Public Policy and Reimbursement in Government Affairs. Before joining Genentech in 2011, Kelly’s career was started in physician specialty societies, working at the American College of Cardiology (ACC) and then the American Academy of Dermatology (AAD). At ACC, she worked on the development of clinical practice guidelines. At the AAD, Kelly was Director of Regulatory and Payment Policy and oversaw the specialty’s engagement with HHS, CMS, and FDA to advocate for the specialty around coverage, coding, reimbursement, and regulatory policy issues.
Kelly holds a Bachelor of Science in Policy Analysis and a Master of Health Administration and Policy from Cornell University. Her passion to shape healthcare systems to be more resilient and deliver better care led her to start a career in healthcare. For many years she has been leading policy and regulatory engagements for medical associations in the U.S. before she joined Genentech’s policy team in 2011.
Throughout her career in healthcare, Kelly has valued the impact of partnerships to change healthcare systems and shape healthcare ecosystems that enable people access to innovative care solutions.
Who Should Enroll
- Pharmaceutical professionals involved in marketing, sales, medical affairs, managed markets, manufacturing, or distribution
- Biotechnology professionals
- Health insurance professionals
- Anyone looking to understand business, economic and policy issues affecting biopharmaceutical organizations
cornell's Top Minds